Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRF114 (Surface Oncology)
- Development stage
- Unknown
- Lead developer
- Coherus BioSciences
- Modality
- Antibody-Based Therapeutics
01
Overview
SRF114 (Surface Oncology): sourced facts only. name: "SRF114, a highly selective human anti-CCR8 afucosylated antibody, and an anti-mouse CCR8 antibody were utilized to preferentially deplete CCR8+ Treg cells in human CCR8 knock-in (hCCR8KI) or wild-type mice, respectively." [DOI:10.1158/1538-7445.am2023-5125]; target: "SRF114, a highly selective human anti-CCR8 afucosylated antibody, and an anti-mouse CCR8 antibody were utilized to preferentially deplete CCR8+ Treg cells in human CCR8 knock-in (hCCR8KI) or wild-type mice, respectively." [DOI:10.1158/1538-7445.am2023-5125]; developer: "1Surface Oncology, Inc., Cambridge, MA." [DOI:10.1158/1538-7445.am2023-5125]; modality: "SRF114, a highly selective human anti-CCR8 afucosylated antibody, and an anti-mouse CCR8 antibody were utilized to preferentially deplete CCR8+ Treg cells in human CCR8 knock-in (hCCR8KI) or wild-type mice, respectively." [DOI:10.1158/1538-7445.am2023-5125]; stage: "Treatment with SRF114 or anti-mouse CCR8 antibody resulted in robust monotherapy activity in models susceptible to CPI." [DOI:10.1158/1538-7445.am2023-5125]
02
Targets
CCR8
Beyond the preview
Go deeper on SRF114 (Surface Oncology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SRF114 (Surface Oncology).